Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV-RS1 Gene Therapy for X-linked Retinoschisis
NCT02317887Phase 2Completed
- Sponsor
- VegaVect
- Start
- Feb 2015
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of RS1 AAV vector in X-linked juvenile retinoschisis (XLRS) (6 cohorts), sponsored by VegaVect. Primary endpoint: Adverse Events Affecting Ocular Function at 2 years. Started Feb 2015; status: completed.
02
Drugs
RS1 AAV vector
03
Conditions
X-linked juvenile retinoschisis (XLRS)
Beyond the preview
Go deeper on NCT02317887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317887.